Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib

J Thorac Oncol. 2018 Jul;13(7):e124-e126. doi: 10.1016/j.jtho.2018.02.030.

Authors

Wenjuan Jiang¹, Nong Yang¹, Yongchang Zhang²

Affiliations

¹ Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China.
² Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China. Electronic address: [email protected].

PMID: 29935852
DOI: 10.1016/j.jtho.2018.02.030

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / genetics
Crizotinib / pharmacology*
Drug Resistance, Neoplasm*
Exons*
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics
Lung Neoplasms / pathology*
Male
Middle Aged
Prognosis
Protein Kinase Inhibitors / pharmacology
Proto-Oncogene Proteins c-met / antagonists & inhibitors
Proto-Oncogene Proteins c-met / genetics*

Substances

Protein Kinase Inhibitors
Crizotinib
MET protein, human
Proto-Oncogene Proteins c-met